Le médicament du mois. Le dulaglutide (Trulicity®) : Nouvel agoniste des récepteurs du Glucagon-Like Peptide-1 en injection hebdomadaire pour traiter le diabète de type 2

SCHEEN, André

Article (Scientific journals)

SCHEEN, André

2016 • In Revue Médicale de Liège, 71, p. 154-160

Peer reviewed

Permalink
https://hdl.handle.net/2268/195880

PubMed
27311248

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

201603_09.pdf

Publisher postprint (397.22 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Dual oral therapy; Dulaglutide; Glucagon-like peptide-1; Incretin; Once-weekly administration; Type 2 diabetes

Abstract :

[fr] Résumé : Le dulaglutide (Trulicity®) est un nouvel agoniste des récepteurs du Glucagon-Like Peptide-1 (GLP-1) proposé, en injection sous-cutanée hebdomadaire, dans le traitement du diabète de type 2. Les études cliniques du programme de phase III AWARD ont démontré l’efficacité et la sécurité d’emploi du dulaglutide chez des patients diabétiques de type 2 traités par régime et exercice, par metformine, par une combinaison metformine-sulfamide ou metformine-pioglitazone ou encore par des suppléments d’insuline prandiale. Dans le programme AWARD, le dulaglutide (0,75 ou 1,5 mg en injection sous-cutanée une fois par semaine) exerce un effet anti-hyperglycémiant plus puissant que la metformine, la sitagliptine, l’exénatide ou l’insuline glargine et s’avère non inférieur au liraglutide 1,8 mg une fois par jour. Présenté sous forme d’un stylo pré-rempli pour injection, Trulicity® est actuellement remboursé en Belgique après échec d’une bithérapie orale metformine-sulfamide ou metformine-pioglitazone et en association avec celle-ci.
[en] Summary : Dulaglutide (Trulicity®) is a new once-weekly agonist of Glucagon-Like Peptide-1 (GLP-1) receptors indicated in the treatment of type 2 diabetes. Phase III clinical trials in AWARD programme demonstrated the efficacy and safety of dulaglutide in patients with type 2 diabetes treated by diet and exercise, metformin, a combination of metformin and a sulfonylurea or metformin and pioglitazone or even by supplements of prandial insulin. In the AWARD programme, dulaglutide (subcutaneous 0.75 or 1.5 mg once weekly) exerted a greater glucose-lowering activity than metformin, sitagliptin, exenatide or insulin glargine, and was non-inferior to liraglutide 1.8 mg once daily. Dulaglutide is currently reimbursed in Belgium after failure of and in combination with a dual oral therapy with metformin and a sulfonylurea or metformin and pioglitazone.

Disciplines :

Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition

Author, co-author :

SCHEEN, André ; Centre Hospitalier Universitaire de Liège - CHU > Service de diabétologie, nutrition, maladies métaboliques

Language :

French

Title :

Le médicament du mois. Le dulaglutide (Trulicity®) : Nouvel agoniste des récepteurs du Glucagon-Like Peptide-1 en injection hebdomadaire pour traiter le diabète de type 2

Alternative titles :

[en] Dulaglutide (Trulicity®), a new once-weekly agonist of Glucagon-Like Peptide-1 receptors for type 2 diabetes

Publication date :

March 2016

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Pages :

154-160

Peer reviewed :

Peer reviewed

Additional URL :

http://www.rmlg.ulg.ac.be

Available on ORBi :

since 21 April 2016

Statistics

Number of views

838 (7 by ULiège)

Number of downloads

1204 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Scheen AJ, Paquot N. - Actualisation 2015 des recommandations américaines et européennes pour le traitement du diabète de type 2. Rev Med Liege, 2015, 70, 122-128.
Scheen AJ, Van Gaal LF. - Exénatide (Byetta®). Incrétinomimétique indiqué dans le traitement du diabète de type 2 après échec et en complément des antidiabétiques oraux. Rev Med Liege, 2008, 63, 158-165.
Scheen AJ, Van Gaal LF. - Liraglutide (Victoza®): analogue du glucagon-like peptide-1 humain en une injection par jour pour le traitement du diabète de type 2. Rev Med Liege, 2010, 65, 464-470.
Scheen AJ. - Le lixisénatide (Lyxumia®) : nouvel agoniste des récepteurs du glucagon-like peptide-1 à action préférentiellement post-prandiale. Rev Med Liege, 2014, 69, 102-109.
Scheen AJ. - Bydureon® : premier agoniste des récepteurs du GLP-1 en une injection hebdomadaire (exénatide à libération prolongée). Rev Med Liege, 2014, 69, 214-219.
Scheen AJ. - L'albiglutide (Eperzan®) : nouvel agoniste des récepteurs du glucagon-like peptide-1 en injection hebdomadaire. Rev Med Liege, 2015, 70, 207-214.
Sanford M. - Dulaglutide: first global approval. Drugs, 2014, 74, 2097-2103.
Thompson AM, Trujillo JM. - Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes. Ann Pharmacother, 2015, 49, 351-359.
Scheen AJ. - Dulaglutide (LY-2189265) for the treatment of type 2 diabetes. Expert Rev Clin Pharmacol, 2016, Feb 6:1-15. [Epub ahead of print].
Scheen AJ. - Which incretin-based therapy for type 2 diabetes ? Lancet, 2014, 384, 1325-1327.
Zaccardi F, Htike ZZ, Webb DR, et al. - Benefits and harms of once-weekly glucagon-like peptide-1 receptor agonist treatments: a systematic review and network meta-analysis. Ann Intern Med, 2016, 164, 102-113.
Geiser JS, Heathman MA, Cui X, et al. - Clinical pharmacokinetics of dulaglutide in patients with type 2 diabetes: analyses of data from clinical trials. Clin Pharmacokinet, 2015, Oct 27. [Epub ahead of print].
Scheen AJ. - Le glucagon-like peptide-1 (GLP-1), nouvelle cible dans le traitement du diabète de type 2. Rev Med Liege, 2007, 62, 217-221.
Grunberger G, Chang A, Garcia Soria G, et al. - Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med, 2012, 29, 1260-1267.
Terauchi Y, Satoi Y, Takeuchi M, et al. - Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebocontrolled study. Endocr J, 2014, 61, 949-959.
Umpierrez G, Tofe Povedano S, Perez Manghi F, et al. - Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care, 2014, 37, 2168-2176.
Miyagawa JI, Odawara M, Takamura T, et al. - Once weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomised phase 3 study. Diabetes Obes Metab, 2015, 17, 974-983.
Odawara M, Miyagawa J, Iwamoto N, et al. - Once weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases HbA1c compared with once daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study. Diabetes Obes Metab, 2016, 18, 249-257.
Nauck M, Weinstock RS, Umpierrez GE, et al. - Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care, 2014, 37, 2149-2158.
Weinstock RS, Guerci B, Umpierrez G, et al. - Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab, 2015, 17, 849-858.
Dungan KM, Povedano ST, Forst T, et al. - Onceweekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, noninferiority trial. Lancet, 2014, 384, 1349-1357.
Dungan KM, Weitgasser R, Perez Manghi F, et al. - A 24-week study to evaluate the efficacy and safety of once weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8). Diabetes Obes Metab, 2016, Jan 22. doi: 10.1111/dom.12634. [Epub ahead of print].
Giorgino F, Benroubi M, Sun JH, et al. - Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care, 2015, 38, 2241-2249.
Araki E, Inagaki N, Tanizawa Y, et al. - Efficacy and safety of once weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once daily insulin glargine in Japanese patients with type 2 diabetes: a randomised, open-label, phase 3, noninferiority study. Diabetes Obes Metab, 2015, 17, 994-1002.
Wysham C, Blevins T, Arakaki R, et al. - Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care, 2014, 37, 2159-2167.
Reaney M, Yu M, Lakshmanan M, et al. - Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes Obes Metab, 2015, 17, 896-903.
Scheen AJ, Paquot N. - Rationnel en faveur d'une combinaison insuline basale-incrétine pour traiter le diabète de type 2. Rev Med Liege, 2013, 68, 562-568.
Blonde L, Jendle J, Gross J, et al. - Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, openlabel, phase 3, non-inferiority study. Lancet, 2015, 385, 2057-2066.
Matfin G, Van Brunt K, Zimmermann AG, et al. - Safe and effective use of the once weekly dulaglutide single-dose pen in injection-naïve patients with type 2 diabetes. J Diabetes Sci Technol, 2015, 21, 1071-1079.